0.4128
Schlusskurs vom Vortag:
$0.458
Offen:
$0.44
24-Stunden-Volumen:
140.38K
Relative Volume:
0.26
Marktkapitalisierung:
$16.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.67M
KGV:
-0.1336
EPS:
-3.09
Netto-Cashflow:
$-101.06M
1W Leistung:
-4.22%
1M Leistung:
+39.93%
6M Leistung:
-20.48%
1J Leistung:
-87.53%
Athira Pharma Inc Stock (ATHA) Company Profile
Firmenname
Athira Pharma Inc
Sektor
Branche
Telefon
(425) 620-8501
Adresse
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Vergleichen Sie ATHA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ATHA
Athira Pharma Inc
|
0.4128 | 17.88M | 0 | -117.67M | -101.06M | -3.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-09-19 | Herabstufung | Mizuho | Outperform → Neutral |
2024-09-04 | Herabstufung | BTIG Research | Buy → Neutral |
2024-09-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2024-09-04 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
2024-08-19 | Eingeleitet | Rodman & Renshaw | Buy |
2022-10-17 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
2022-07-07 | Eingeleitet | Mizuho | Buy |
2022-06-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2022-06-23 | Herabstufung | Jefferies | Buy → Hold |
2022-06-23 | Herabstufung | Stifel | Buy → Hold |
2022-05-10 | Eingeleitet | BTIG Research | Buy |
2022-04-21 | Eingeleitet | Berenberg | Buy |
2021-12-15 | Eingeleitet | Goldman | Neutral |
2020-10-13 | Eingeleitet | Goldman | Buy |
2020-10-13 | Eingeleitet | JMP Securities | Mkt Outperform |
2020-10-13 | Eingeleitet | Jefferies | Buy |
2020-10-13 | Eingeleitet | Stifel | Buy |
Alle ansehen
Athira Pharma Inc Aktie (ATHA) Neueste Nachrichten
What are Athira Pharma Inc. company’s key revenue driversCapitalize on momentum-driven investment opportunities - jammulinksnews.com
Reversal indicators forming on Athira Pharma Inc. stockShort-Term Profit Alert With Entry Forecast - Newser
Is it the right time to buy Athira Pharma Inc. stockGet daily expert analysis for smarter investing - jammulinksnews.com
Sector ETF performance correlation with Athira Pharma Inc. Smart Stock Forecast Using AI Algorithms - Newser
What is Athira Pharma Inc. company’s growth strategyInvest confidently with expert support - jammulinksnews.com
What makes Athira Pharma Inc. stock price move sharplyUnlock exclusive investment alerts - jammulinksnews.com
What are the latest earnings results for Athira Pharma Inc.Unprecedented growth rates - jammulinksnews.com
Published on: 2025-07-27 20:04:45 - jammulinksnews.com
Athira Pharma Inc. Earnings Report Breakdown: What Investors Should KnowFree Trading Strategy Suggestions - Newser
How Athira Pharma Inc. stock performs during market volatilitySolid Return Trade Selections - Newser
Buy Signal for Athira Pharma Inc. Stock Key Technical Indicators to WatchFree Stock Market Return Analysis - Newser
Why Athira Pharma Inc. stock attracts strong analyst attentionSteady Profit Stock Forecasts - Newser
Is Athira Pharma Inc. a good long term investmentMarket-crushing profits - PrintWeekIndia
Athira Pharma Inc. Stock Analysis and ForecastUnprecedented profits - Autocar Professional
What drives Athira Pharma Inc. stock priceHigh-yield capital appreciation - jammulinksnews.com
What analysts say about Athira Pharma Inc. stockSkyrocketing investment returns - jammulinksnews.com
Athira Pharma (NASDAQ:ATHA) Trading Up 8.4% – Here’s Why - Defense World
Investors Can Still File Late Claims in Athira Pharma Settlement — Here’s How to Get Your Share - TradingView
Lewy Body Dementia Market Set to Grow Substantially Through - openPR.com
Athira Pharma (ATHA) Is Paying a $10M Settlement to Investors — Here’s How to Get Your Share - TradingView
Is Athira Pharma, Inc. technically bullish or bearish? - MarketsMojo
Two Sigma Advisers LP Has $149,000 Position in Athira Pharma, Inc. (NASDAQ:ATHA) - Defense World
ATHA LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Athira Pharma, Inc. Investors with LARGE LOSSES to Secure Counsel Before Important Deadline in Securities Class Action – ATHA - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Athira Pharma (NASDAQ:ATHA) Trading 9.2% Higher – Here’s Why - Defense World
HAGENS BERMAN, NATIONAL ATTORNEYS, Alerts Athira Pharma (ATHA) Investors to Filing Of Securities Class Action, Advises Investors with Losses to Contact Firm's Attorneys Now - ACCESS Newswire
Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022 - Barchart.com
Athira Pharma Holds Annual Stockholders Meeting - TipRanks
Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022 - Barchart.com
This Athira Pharma Insider Increased Their Holding By 111% Last Year - Yahoo Finance
Athira Pharma’s SWOT analysis: als drug developer’s stock faces pivotal phase - Investing.com
Athira Pharma (ATHA) Highlights Promising Phase 1 Results for ALS Drug Candidate | ATHA Stock News - GuruFocus
Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 - Yahoo Finance
Athira Pharma (ATHA) Projected to Post Earnings on Wednesday - Defense World
Athira Pharma Reports Reduced Losses and Strategic Focus - MSN
Finanzdaten der Athira Pharma Inc-Aktie (ATHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):